Tag Archives: 00q4

Targeting Trends Newsletter 00q4

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page. Newsletter Highlights Toxicology/Safety studies with SP-SAP to begin (page 1-2) Second immunotoxins: use your monoclonal or polyclonal to target cells (page 5) Mouse p75 immunotoxin to be […]

Targeting Tools: ME20.4 Monoclonal and Immunotoxin

The ME20.4 monoclonal antibody (Cat. #AB-N07) was derived from immunization of mice with WM245 melanoma cells. The antibody can be used in Western blot, immunoprecipitation, immunohistochemistry, FACS analysis, and electron microscopy. The known species reactivity includes human, primate, rabbit, raccoon, dog, cat, and sheep. The ME20.4-SAP immunotoxin (Cat. #IT-15) is a chemical conjugation between the […]

Targeting Tools: Mouse-Specific p75 Immunotoxin

The long-sought mouse cholinergic toxin has been found! The mouse cholinergic immunotoxin (Cat. #IT-16) is being released for sale at the Society for Neuroscience meeting in New Orleans, November 4-9, 2000! For years ATS has received requests for a molecule that would eliminate cholinergic neurons in the basal forebrain of mice in a manner that […]

Targeting Talk: Second Immunotoxins

What is a second immunotoxin? ATS’s second immunotoxins are conjugations of a secondary antibody (as of December 2000, either goat anti-mouse IgG or goat anti-rabbit IgG) to the ribosome-inactivating protein, saporin. How does a second immunotoxin target? The second immunotoxin uses the secondary antibody to “piggyback” onto your primary antibody in order to evaluate the […]

Targeting Topics 00q4

Impaired acquisition of a Morris water maze task following selective destruction of cerebellar purkinje cells with OX7-saporin. Gandhi CC, Kelly1 RM, Wiley RG, Walsh TJ. Behav Brain Res 109(1):37-47, 2000. PMID: 10699656 The cerebellum has been associated with the control of motor activity and voluntary movements. Recent data have shown the cerebellum may also play […]

NIDA funds ATS research on Galanin

Advanced Targeting Systems (ATS) has just been awarded a $100,000 research grant from the National Institute on Drug Abuse (NIDA). This Phase I SBIR (Small Business Innovation Research) grant proposes to develop a research reagent to study the function of the neuropeptide, galanin. This will be an important tool for scientists to use in the […]

Cover Article: CBF Lesioning in Rabbits

Contributed by Dr. Thomas Beach, Sun Health Research Institute, Sun City, AZ Our hypothesis, developed through our own human and animal studies1-6 and the cell culture work of others (beginning with Nitsch7), is that the normal, age-related loss of cortical cholinergic innervation leads to Aβ deposition and Alzheimer’s disease. To test this hypothesis, we have been […]